Anticoagulant Therapy is a type of medication that helps prevent blood clots from forming or growing larger. In this trial, it is used to reduce the risk of bleeding in patients who have experienced a venous thromboembolism (VTE), which is a condition where blood clots form in the veins. The goal is to see if using only this medication is better at preventing bleeding compared to using it together with another type of medication.

Antiplatelet Therapy is a medication that helps stop blood cells called platelets from sticking together and forming clots. This therapy is often used to prevent clots in arteries, which can lead to heart attacks or strokes. In this trial, patients are already taking this medication for preventing artery-related issues, and the study is looking at how it works when combined with anticoagulant therapy in patients who have had a VTE.

Acute Venous Thromboembolism – Acute venous thromboembolism (VTE) is a condition where blood clots form in the veins, typically in the deep veins of the legs, known as deep vein thrombosis (DVT), or in the lungs, known as pulmonary embolism (PE). The disease begins with the formation of a blood clot that can partially or completely block blood flow in the affected vein. If the clot dislodges, it can travel through the bloodstream and lodge in the lungs, causing a pulmonary embolism. Symptoms of DVT may include swelling, pain, and redness in the affected leg, while PE may cause shortness of breath, chest pain, and coughing. The progression of the disease can lead to complications such as post-thrombotic syndrome, characterized by chronic pain and swelling, or post-PE syndrome, which involves persistent respiratory issues. The condition requires careful management to prevent further clotting and associated complications.